Conatus Pharmaceuticals Inc. (CNAT) to Post FY2017 Earnings of ($0.64) Per Share, Seaport Global Securities Forecasts
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) – Seaport Global Securities lifted their FY2017 earnings per share estimates for Conatus Pharmaceuticals in a note issued to investors on Thursday. Seaport Global Securities analyst V. Bernardino now anticipates that the biotechnology company will post earnings per share of ($0.64) for the year, up from their prior estimate of ($0.71). Seaport Global Securities has a “Buy” rating and a $16.00 price objective on the stock. Seaport Global Securities also issued estimates for Conatus Pharmaceuticals’ Q4 2017 earnings at ($0.12) EPS and FY2018 earnings at $2.24 EPS.
Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.08). Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. The company had revenue of $9.57 million for the quarter, compared to analyst estimates of $16.06 million. During the same quarter in the prior year, the company earned ($0.31) earnings per share. ILLEGAL ACTIVITY NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/11/08/conatus-pharmaceuticals-inc-cnat-to-post-fy2017-earnings-of-0-64-per-share-seaport-global-securities-forecasts.html.
A number of other brokerages have also weighed in on CNAT. Zacks Investment Research upgraded Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. HC Wainwright restated a “buy” rating and issued a $17.00 target price (down from $18.00) on shares of Conatus Pharmaceuticals in a research note on Thursday, November 2nd. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $10.00 price objective on shares of Conatus Pharmaceuticals in a research report on Thursday, August 3rd. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Conatus Pharmaceuticals has a consensus rating of “Buy” and an average target price of $16.00.
Conatus Pharmaceuticals (CNAT) opened at $4.13 on Monday. The company has a quick ratio of 2.77, a current ratio of 2.69 and a debt-to-equity ratio of 0.41. Conatus Pharmaceuticals has a 12 month low of $1.51 and a 12 month high of $9.40.
A number of institutional investors and hedge funds have recently modified their holdings of CNAT. Acadian Asset Management LLC boosted its holdings in Conatus Pharmaceuticals by 641.1% during the second quarter. Acadian Asset Management LLC now owns 1,097,945 shares of the biotechnology company’s stock worth $6,324,000 after buying an additional 949,785 shares during the last quarter. State Street Corp bought a new position in Conatus Pharmaceuticals during the second quarter worth about $2,092,000. Numeric Investors LLC bought a new position in shares of Conatus Pharmaceuticals during the 2nd quarter valued at about $1,620,000. Northern Trust Corp lifted its holdings in shares of Conatus Pharmaceuticals by 640.6% during the 2nd quarter. Northern Trust Corp now owns 297,152 shares of the biotechnology company’s stock valued at $1,712,000 after purchasing an additional 257,030 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Conatus Pharmaceuticals by 31.2% during the 2nd quarter. Vanguard Group Inc. now owns 1,006,890 shares of the biotechnology company’s stock valued at $5,800,000 after purchasing an additional 239,373 shares in the last quarter. Hedge funds and other institutional investors own 33.04% of the company’s stock.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Stock Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.